Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

743.97 +6.14 (+0.83%)
Streaming Delayed Price Updated: 3:37 PM EDT, Sep 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
FDA Breakthrough Status Awarded To Lilly-Merck Combo Drug For Advanced Non-Small Cell Lung Cancer
Eli Lilly's olomorasib with Merck's Keytruda receives FDA Breakthrough Therapy status for KRAS G12c lung cancer, supported by trial results. 
Via Benzinga
ETF Traders Are Quietly Positioning For Market Turbulence: Direxion
Direxion MD Edward Egilinsky says traders are locking profits, hedging market highs, and using Palantir inverse ETFs for tactical moves. 
Via Benzinga
Topics ETFs
Prediction: These 2 Biotech Stocks Could Double in the Next 5 Years
Both companies have made significant progress in recent years. 
Via The Motley Fool
The 6 Best Stocks to Buy Right Now in September (2025)!
There is something for everyone in this list of excellent stocks to buy. 
Via The Motley Fool
Chinese Drugmakers Flooded US With Wegovy Copy Ingredients — Now They Are Pivoting To Generics: Report
Via Stocktwits
Where Will Eli Lilly Be in 3 Years?
The weight-loss drug opportunity could approach $100 billion by the end of the decade. 
Via The Motley Fool
Topics Intellectual Property
The Problem With Weight Loss Stocks
There are new ways to tackle weight loss, but the stocks leading the way are lagging. 
Via The Motley Fool
Topics Economy
After Copycat Boom, China's Drugmakers Target Global Generics
Chinese suppliers of semaglutide and tirzepatide that fueled a U.S. weight-loss drug boom are pivoting to generics as FDA crackdowns. 
Via Benzinga
Topics Supply Chain
This House of Representative Just Bought Up To $245K In Eli Lilly Stock
 
Via Benzinga
Is Novo Nordisk Stock a Buy Now?
A 57% risk reduction for heart attacks and strokes sounds like an amazing result. 
Via The Motley Fool
Inflation's Stubborn Grip: PCE Index and Fed's Dilemma
The specter of persistent inflation continues to loom large over the U.S. economy, keeping both consumers and policymakers on edge. Despite the Federal Reserve's aggressive campaign of interest rate... 
Via MarketMinute
Topics Bonds Economy Supply Chain
EXCLUSIVE: August's 20 Most-Searched Tickers On Benzinga Pro – Where Do Opendoor, Palantir, BitMine Immersion, Apple Stock Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
Novo Nordisk's Wegovy Outshines Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke And Death
Novo Nordisk's Wegovy cut cardiovascular risks significantly versus tirzepatide in a real-world study, showing fewer heart attacks, strokes, and deaths. 
Via Benzinga
Unpacking Q2 Earnings: Elanco (NYSE:ELAN) In The Context Of Other Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Elanco (NYSE:ELAN) and the best and worst... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Benzinga Bulls And Bears: Eli Lilly, Firefly, Marvell — And Trump Investment Hints Boost Defense Stocks
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Topics Government
FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment
This could put pressure on Eli Lilly, which sells a competing drug called Kisunla. 
Via Investor's Business Daily
The Great Rebalancing: Equity Markets Pivot from Tech Giants to Value and Cyclical Stocks
A significant sector rotation is currently underway in equity markets, shifting investor capital away from the mega-cap technology stocks that dominated recent years towards more traditional value and... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Eli Lilly Is Proof That Wall Street Stars Don't Have To Be Tech Titans
 
Via Benzinga
Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook
Novo Nordisk alone contributing one-fifth of employment gains to Denmark. But economic headwinds are mounting. 
Via Benzinga
FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy
The FDA now requires earlier MRI screening for Alzheimer's drug Leqembi to detect ARIA-E, a rare but serious side effect, aiming to improve treatment safety for patients. 
Via Benzinga
Nvidia's $46.7 Billion Quarter Shows the AI Trade Is Alive and Well -- With Caveats
Here's why investors aren't sure what to make of Nvidia earnings. 
Via The Motley Fool
Topics Artificial Intelligence
2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts
Investment bank analysts up and down Wall Street are pounding the table on these stocks. 
Via The Motley Fool
The Unsettling Dance: Robust Growth and Stubborn Inflation Challenge the Fed's Resolve
The U.S. economy currently navigates an intriguing, yet precarious, path as hypothetical Q2 2025 data suggests a robust rebound in Gross Domestic Product (GDP) growth. This economic buoyancy, however,... 
Via MarketMinute
Topics Bonds Economy Energy
Stock Of The Day: Another Breakout For Eli Lilly?
Shares of Eli Lilly (LLY) are testing a resistance level. If they can break through this resistance, a large more higher may follow. 
Via Benzinga
Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study
Prothena reported ASCENT trial data showing strong amyloid plaque reduction but high ARIA-E rates for Alzheimer's drug PRX012, prompting a shift in focus. 
Via Benzinga
Global Trade Braces for Impact: US-China Tariff Tensions Persist Amidst Fleeting Truces and Escalating Duties
The global economic landscape remains deeply entrenched in a complex and often volatile trade conflict between the United States and China. What began in January 2018 as a series of targeted duties has... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
This Pharma Major’s Stock Has Lost 59% Of Its Value In A Year – Why Is It Drawing Investor Interest Today?
Novo Nordisk has entered into a collaboration with Replicate BioScience under which it will receive a defined, exclusive, worldwide license to use the latter’s self-replicating RNA platform to develop... 
Via Stocktwits
2 Growth Stocks That Could Be Worth $1 Trillion in 5 Years
These two longtime market leaders should continue to perform well. 
Via The Motley Fool
Novo Nordisk Eyes New Arena Amid Weight-Loss Market Pressure
Novo Nordisk stock remains under pressure this year. But the company is now launching Wegovy in MASH treatment. 
Via Investor's Business Daily
The Invesco QQQ Trust Has a Glaring Flaw by Excluding This "Ten Titans" Stock and 3 Other Megacap Growth Stocks. Here's an ETF That Corrects the Error.
Investors looking for top growth stocks on the Nasdaq and NYSE may want to consider alternatives to the Invesco QQQ. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.